The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024, rose to US$10.5 billion in 2025, and is projected to expand at a powerful CAGR of 18.6% from 2025 to 2030, reaching a remarkable US$24.7 billion by the end of the forecast period. This rapid trajectory reflects the growing utility of synthesized oligonucleotides across therapeutics, diagnostics, synthetic biology, and advanced research applications.
Oligonucleotides—short DNA or RNA sequences—have emerged as indispensable tools in genetic medicine, enabling targeted modulation of gene expression and precision sequence manipulation. With the surge of genomic research, personalized medicine, and innovative therapeutic modalities, the market is entering a stage of accelerated expansion.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Market Growth Drivers: The Rise of Genetic Medicine & Advanced Research
The demand for synthesized oligonucleotides is being fueled by transformative trends in the life sciences ecosystem. Their widening adoption in therapeutics, particularly antisense therapies and RNA interference (RNAi), has been a core contributor. Rapid progress in precision medicine has positioned oligonucleotides as key components in targeted treatments for oncology, neurology, infectious diseases, and rare genetic disorders.
Technological advancements—spanning high-throughput synthesis platforms, improved purification technologies, and automation—have significantly enhanced yield and structural accuracy. Additionally, expanding investments in synthetic biology, gene editing, CRISPR workflows, and mRNA technology (especially after the COVID-19 vaccine success) have strengthened market growth.
Emerging economies are witnessing accelerated R&D investments from both global and regional players, opening new avenues for market penetration and partnerships.
Market Segmentation: Antisense Oligonucleotide Drugs Lead the Way
By Product
The market is segmented into:
-
Antisense oligonucleotide (ASO)-based drugs
-
siRNA oligonucleotide-based drugs
-
Other oligonucleotide-based drugs
In 2024, ASOs dominated the market, accounting for the largest share. ASOs are short single-stranded molecules that selectively bind to RNA targets, enabling gene expression modulation—a highly targeted approach increasingly preferred for rare genetic and neurological diseases.
Landmark regulatory approvals such as:
-
Nusinersen (Spinraza) for spinal muscular atrophy
-
Inotersen for hereditary ATTR amyloidosis
have validated ASO therapies clinically and commercially. These successes have boosted investor confidence, fostering increased manufacturing capacity, new therapeutic pipelines, and expanded global research initiatives.
ASOs also benefit from:
-
High synthesis yield
-
Lower manufacturing complexity
-
Compatibility with established delivery platforms
Together, these advantages underpin their sustained leadership position in the market.
Hospitals Dominate the End-User Landscape
By End User
The market includes the following segments:
-
Hospitals
-
Pharmaceutical & biotechnology companies
-
Diagnostic laboratories
-
CROs & CMOs
In 2024, hospitals accounted for the largest share, driven by the increasing demand for oligonucleotide-based therapies for rare, neurological, and chronic diseases. The growing target patient population has strengthened the clinical adoption of oligonucleotide therapies in hospital settings.
Hospitals also play a critical role in delivering personalized medicine, ranging from genetic diagnostics to targeted oligonucleotide therapeutics. Rising prevalence of chronic and infectious diseases further supports the demand for precision therapeutics.
North America Leads the Global Market
Geographical Insights
In 2024, North America dominated the global market, supported by:
-
Strong regional players with advanced manufacturing infrastructure
-
A robust supply-chain ecosystem
-
Favorable regulatory frameworks by the USFDA and Health Canada
-
Accelerating product commercialization and biotech innovation
The region’s ecosystem of academic institutions, biotech startups, and large pharmaceutical companies continues to drive research collaborations and scale-up production. These factors collectively consolidate North America’s leadership in the oligonucleotide synthesis space.
Competitive Landscape: Key Players Shaping the Future
The market is moderately consolidated, with leading companies expanding their global footprint through capacity expansion, acquisitions, and technological innovation.
Major players include:
-
Danaher Corporation (US)
-
Thermo Fisher Scientific Inc. (US)
-
Merck KGaA (Germany)
-
Eurofins Scientific (Luxembourg)
-
LGC Limited (UK)
-
Agilent Technologies (US)
-
Kaneka Corporation (Japan)
-
Maravai LifeSciences (US)
-
Azenta US Inc. (US)
-
Twist Bioscience (US)
-
GenScript (US)
Company Highlights
Danaher Corporation / Integrated DNA Technologies (IDT)
Danaher, through IDT and Cytiva, commands a strong presence in oligonucleotide synthesis. IDT offers:
-
Custom & pre-designed primers
-
Probes
-
Therapeutic oligonucleotides (including ASOs)
-
Synthesis equipment
In 2023, IDT expanded its footprint by launching a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa, designed for cGMP-grade production. The facility includes ISO cleanrooms, purification suites, QC labs, and future expansion space—strengthening Danaher’s leadership in cell & gene therapy solutions.
Thermo Fisher Scientific
Thermo Fisher is another major player with a comprehensive portfolio of:
-
Custom & pre-designed DNA/RNA oligos
-
Primers and probes
-
Reagents and consumables
The company has strengthened its position through collaborations and expansions, including a notable partnership with the University of Sheffield to advance workflows for complex oligonucleotide and mRNA characterization. With operations in over 50 countries, Thermo Fisher’s global supply chain remains a key competitive advantage.
Biogen
Biogen plays a crucial role in the oligonucleotide therapeutics market. Key strengths include:
-
The FDA accelerated approval of QALSODY (Tofersen) for ALS
-
Long-standing success of Spinraza, a blockbuster ASO
-
A dedicated oligonucleotide synthesis manufacturing facility in North Carolina
In 2025, Biogen partnered with Stoke Therapeutics to develop and commercialize Zorevunersen, an investigational ASO for Dravet syndrome—demonstrating its continued commitment to genetic medicine.
Conclusion: A Transformative Decade Ahead
The oligonucleotide synthesis market is poised for transformative growth as advancements in genetic therapeutics, diagnostics, and synthetic biology accelerate global demand. Expanding applications, increased regulatory approvals, and rising investments in precision medicine will continue to drive innovation. With strong contributions from North America and growing participation from emerging markets, the industry is set for a decade of robust expansion.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350